Plasma levels of α 1 -antitrypsin-derived C-terminal peptides in PiMM and PiZZ COPD patients.

Plasma levels of α ₁ -antitrypsin-derived C-terminal peptides might be valid as novel biomarkers to predict and/or characterise exacerbations in PiMM and PiZZ COPD patients, or to reflect the efficiency of augmentation therapy in PiZZ patients https://bit.ly/3rNJeLd.
Competing Interests: Conflict of interest: T. Welte reports support for the present manuscript from the German Ministry of Education and Research, and payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Grifols and CSL Behring, outside the submitted work. Conflict of interest: J. Chorostowska-Wynimko reports grants or contracts from AstraZeneca, Pfizer, CSL Behring, Grifols and Mereo Biopharma, outside the submitted work; consulting fees from CSL Behring, Grifols, Mereo Biopharma, Amgen and Pfizer, outside the submitted work; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AstraZeneca, MSD, Pfizer, Takeda, Amgen, Grifols, CSL Behring, Novartis, Chiesi, Celon Pharma and Adamed, outside the submitted work; support for attending meetings and/or travel from MSD, Amgen and Pfizer, outside the submitted work; participation on a data safety monitoring or advisory board for CSL Behring, Grifols and Mereo Biopharma, outside the submitted work; leadership or fiduciary roles in other boards, societies, committees or advocacy groups, paid or unpaid, for the European Respiratory Society, Polish Respiratory Society, International Respiratory Coalition, Polish Coalition for Respiratory Disorders, Polish Coalition for Treatment of Asthma and Polish Foundation for Patients with Alpha-1 Antitrypsin Deficiency, outside the submitted work; and receipt of equipment, materials, drugs, medical writing, gifts or other services from Roche, Biocartis, Amoy, CSL Behring, and Pfizer, outside the submitted work. Conflict of interest: M. Kiehntopf reports that he is inventor of a patent covering a method for quantification of C-terminal peptides of AAT (applicant: Jena University Hospital (JUH); EP22154836.5; status:application), and the inventor of other published patents covering C-terminal AAT peptides in inflammation (applicant: Jena University Hospital (JUH): Method for determining the origin of an infection (EP17719610.2 (application); EP16167699.4 (granted)) and Diagnosis of Sepsis and Systemic Inflammatory Response Syndrome (CN104204808B, EP2592421, EP2780719, US10712350B2, JP6308946B2 (all granted)). Conflict of interest: S. Janciauskiene reports support for the present manuscript from German Center for Lung Research DZL; payment to her institution for research from Excellgene SA and Monthey, Switzerland, outside the submitted work; speaker at the Alpha1 expert meeting, Austria, for Chiesi GmbH, outside the submitted work; support for attending meetings from CSL Behring, outside the submitted work; and is a scientific advisor for the Alpha1 Patient Association, Germany, outside the submitted work. Conflict of interest: The remaining author have nothing to disclose.
(Copyright ©The authors 2023.)